Market evolution: Antibiotic medicines (CN 300420) — 2015–2025

Introduction

This report examines the EU's external trade in medicaments containing antibiotics (excluding penicillins and streptomycins) over the period 2015–2025. The EU is a major global player in this segment, with exports consistently exceeding imports by a wide margin, yielding a trade surplus that expanded from €2.23 billion in 2015 to €2.43 billion in 2025. Over the decade, EU production of these medicaments grew by 25.1% in value terms (from €4.91 billion to €6.14 billion), while the trade landscape was reshaped by shifting partner geographies, a pronounced volume-to-value decoupling, rising import concentration, and deepening trade integration. Three dynamics stand out and structure the analysis below.

1. A Volume-to-Value Decoupling: Falling Quantities, Rising Revenues

EU export volumes declined while export values edged up

The most striking macro-level trend is a clear decoupling between physical trade volumes and their monetary value. EU exports of CN 300420 fell in volume from 44,664 tonnes (2015) to 40,879 tonnes (2025), a contraction of 8.5%, yet their value rose from €3.64 billion to €3.93 billion (+7.9%). This implies a significant increase in unit export values — from €81,549 per tonne in 2015 to €96,047 per tonne in 2025, an increase of 17.8%.

This pattern is consistent with a structural shift toward higher-value, specialised antibiotic formulations — possibly including niche molecules, combination therapies, or advanced delivery forms — rather than bulk generic production. It may also reflect inflation in active pharmaceutical ingredient (API) costs or increased regulatory compliance costs passed through to buyers.

Import prices nearly doubled, driven by a steep volume collapse

On the import side, the dynamic is even more pronounced. EU import volumes plummeted from 13,361 tonnes in 2015 to just 7,415 tonnes in 2025 (−44.5%), yet import values still rose slightly from €1.41 billion to €1.50 billion (+6.0%). The unit import price nearly doubled — from €105,734 per tonne to €201,939 per tonne (+91.0%).

This dramatic price rise at near-halved volumes suggests that the EU increasingly imports only high-value, hard-to-source, or specialised antibiotic medicaments that are not produced domestically in sufficient quantities — while bulk imports have been replaced by domestic production or redirected supply chains. The fact that EU production value grew by 25.1% over the same period supports the hypothesis that the EU has absorbed a portion of the import volume into its own manufacturing base.

The EU's net exporter position has strengthened substantially

These combined trends mean the EU's net import reliance has swung from a modest −8.5% in 2015 to −104.1% in 2025, confirming the EU's position as a strong net exporter in this product category. The trade surplus widened from €2.23 billion to €2.43 billion (+9.0%), and this expansion occurred despite the contraction in overall physical trade volumes, underscoring the value-driven nature of the EU's competitive advantage.

2. A Reorientation of Trade Partners: From the UK and Norway to Switzerland, China, and Emerging Markets

The United Kingdom and Norway have faded as trade partners

The most dramatic partner-level shifts concern the United Kingdom and Norway. EU imports from the UK collapsed from €238 million in 2015 to €89 million in 2025 (−62.8%), and from Norway imports fell from €129 million to just €1.4 million (−98.9%). EU exports to the UK also declined markedly, from €477 million to €257 million (−46.1%).

The UK's departure from the EU single market (Brexit, completed end of 2020) likely accounts for much of this decline, as customs barriers, regulatory divergence, and supply-chain re-routing reduced trade flows. The near-disappearance of Norwegian imports — once the sixth-largest source — may reflect a combination of the high volatility of this trade (coefficient of variation of 1.46, the highest among import partners) and a structural realignment of sourcing.

Switzerland has consolidated its role as the dominant partner

Switzerland emerged as the EU's single largest trade partner for CN 300420 on both the import and export sides. EU imports from Switzerland rose from €425 million to €620 million (+46.0%), while EU exports to Switzerland surged from €673 million to €972 million (+44.5%), having peaked at over €1.51 billion in earlier years. This bilateral intensity reflects Switzerland's role as a major pharmaceutical hub — home to multinationals that both source finished formulations from the EU and supply high-value intermediates or finished products back.

China, Vietnam, and Iraq represent growing export destinations

Among emerging trade partners, China stands out: EU exports to China nearly doubled from €183 million to €335 million (+82.7%), while imports from China remained comparatively modest (rising from €52 million to €61 million, +18.0%). This widening surplus with China suggests the EU is increasingly exporting specialised or branded antibiotic medicaments to the Chinese market, even as China remains a key supplier of APIs and bulk antibiotics globally. EU exports to Vietnam grew by 46.6% (to €80 million), and exports to Iraq more than doubled (+118.7%, to €38 million), pointing to a broader geographic diversification of the EU's export footprint toward Middle Eastern and Southeast Asian markets.

EU member-state trade is dominated by a handful of large players, with notable shifts in ranking

Within the EU, the top exporting member states in 2025 were Belgium (€714 million), Italy (€892 million, up 92.3% from 2015), and the Netherlands (€253 million). Germany, formerly the leading exporter at €812 million in 2015, saw its exports fall to €421 million (−48.1%) — a remarkable decline that may reflect production shifts, corporate relocations, or reclassification of trade flows. Italy's surge and Slovenia's explosive growth (from €39 million to €326 million, +738.6%) suggest a reconfiguration of manufacturing and logistics hubs within the EU. On the import side, Belgium (€341 million), the Netherlands (€262 million), and Slovenia (€278 million) were the leading importers, with the Netherlands more than doubling its import bill.

3. Rising Import Concentration and Deepening Openness: Strategic Implications

Import market concentration has increased markedly

The Herfindahl-Hirschman Index (HHI) for EU imports by value rose from 2,215 in 2015 to 3,273 in 2025 (+47.8%), crossing into territory that signals a moderately concentrated market. By contrast, the export-side HHI remained relatively low (from 860 to 922, +7.2%), indicating that the EU sells to a diversified set of buyers. The rising import concentration means that a growing share of the EU's inbound antibiotic medicament trade is channelled through fewer supplier countries — principally Switzerland and the United States (which alone accounted for €565 million of imports in 2025, +36.3% over the period). This narrowing of the import base raises supply-chain resilience concerns, particularly in a product category with direct public-health implications.

Trade intensity and export propensity have surged

The EU's trade intensity (total extra-EU trade as a share of production) rose from 48.2% in 2015 to 78.1% in 2025, while export propensity (extra-EU exports as a share of production) more than doubled from 34.4% to 73.2%. These figures indicate that EU production of antibiotic medicaments has become significantly more oriented toward global markets over the decade. While this signals competitiveness, it also implies greater exposure to external demand shocks, trade-policy disruptions, or geopolitical tensions.

Geographical specialisation remains concentrated in a few member states

In terms of revealed comparative advantage, the most specialised EU exporters of CN 300420 in 2025 were Cyprus (RSCA: 0.91), Greece (0.75), Croatia (0.63), Slovenia (0.55), and Ireland (0.54). Among large economies, Ireland stands out for its high specialisation (RCA of 3.37), consistent with its role as a pharmaceutical manufacturing hub. At the other end, Sweden, Latvia, Slovakia, and Finland show negative RSCA values, indicating they are net importers with little export specialisation in this product. This uneven distribution underscores the dependency of smaller EU markets on a handful of specialised producing countries for their antibiotic medicine supply.

Conclusion

The EU's trade in antibiotic medicaments (CN 300420) over 2015–2025 has been characterised by three converging dynamics: a value-over-volume shift that has raised unit prices substantially on both the export and import sides; a significant reorientation of trade partners — with the UK and Norway receding while Switzerland, China, Vietnam, and Middle Eastern markets have gained prominence; and a rising concentration of imports coupled with deepening trade integration. The EU has strengthened its position as a net exporter, with its trade surplus growing to €2.43 billion and export propensity reaching 73.2% of domestic production. However, the sharp rise in import concentration (HHI reaching 3,273) and the near-doubling of unit import prices suggest growing dependence on a narrower set of high-value suppliers. For policymakers, these trends highlight both the EU's competitive strength in specialised antibiotic formulations and the strategic importance of maintaining diversified, resilient supply chains in a product category critical to public health.